Drug Development Solutions

  1. Transient Expression Platform: discoCHO 10/4/2024

    Learn how this transient platform accelerates biologics production, seamlessly transitioning from discovery to stable CHO-K1, ensuring scalability, and reducing risks in manufacturing therapeutic biologics.

  2. LC/MS/MS Vs. LC/HRMS: Identifying And Quantifying Oligonucleotides 2/5/2025

    As OGNT-based therapeutics continue to gain traction in drug development, precise identification and quantification are essential for ensuring their efficacy and safety.

  3. Comprehensive Services For Ophthalmic Drug Development 4/9/2024

    With our specialized support, you can be confident that your ophthalmic drug will not only meet regulatory standards but also address unmet medical needs in the most expedited manner possible.

  4. End-to-End Services In Vaccines, CGTs, And Biologics 7/25/2023

    IDT Biologika provides end-to-end services in contract development and manufacturing of vaccines, cell and gene therapeutics, and fill/finish of biologics.

  5. Early Development: Accelerating Molecules Through To Proof-Of-Concept 3/3/2022

    Our integrated approach brings together drug substance, drug product and clinical activities, supporting the expediting of lead molecules from FIH into POC trials.

  6. Comprehensive Characterization Of Biologics 3/27/2025

    Biophysical characterization is crucial for ensuring the stability, integrity, and efficacy of biologics and biosimilars throughout development, formulation, and stability assessments.

  7. Integrated Programs To Bridge Molecules From Discovery Into Clinical Development 1/4/2023

    A new collaboration helps to remove obstacles from the critical path, reduce development risks, eliminate the white space in pre-clinical drug development, and shorten the pathway to clinical development.

  8. Testing At WuXi Advanced Therapies 3/21/2024

    Learn how a partner offering a comprehensive suite of integrated testing services designed to navigate the complexities of cell and gene therapies is critical for accelerating development timelines.

  9. A CDMO With Oral Solid Dose And Sterile Injectable Expertise 6/6/2022

    Societal specializes in modified-release formulations, including those for high potent and DEA controlled substances.

  10. Surfactant Analysis Services

    Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.